Hydrochlorothiazide classification
Pro Research Analysisby 
Searched over 200M research papers for "hydrochlorothiazide classification"
Hydrochlorothiazide Classification and Biopharmaceutical Properties
Introduction to Hydrochlorothiazide
Hydrochlorothiazide (HCTZ) is a widely used thiazide diuretic primarily prescribed for the treatment of hypertension. It is one of the most commonly prescribed antihypertensive medications in the United States, often recommended as a first-line treatment . Despite its widespread use, HCTZ has several limitations related to its biopharmaceutical properties.
Biopharmaceutical Classification System (BCS) Class IV
Hydrochlorothiazide is classified as a Class IV drug under the Biopharmaceutical Classification System (BCS). This classification indicates that HCTZ has low solubility and low permeability, which results in poor absorption in the gastrointestinal tract 1236+1 MORE. These properties significantly affect its oral bioavailability and therapeutic efficacy.
Challenges and Strategies for Solubility and Permeability Enhancement
Cyclodextrin Inclusion Complexes
One approach to improve the solubility and stability of HCTZ is the formation of inclusion complexes with cyclodextrins. Studies have shown that β-cyclodextrin can enhance the solubility of HCTZ, leading to better in vitro and in vivo performance. The inclusion complexes formed by co-evaporation, kneading followed by freeze-drying, and spray-drying methods have shown improved solubility and diuretic activity .
Nanoparticle Formulations
Nanoparticle technology has also been explored to enhance the solubility of HCTZ. Using methods like antisolvent precipitation and emulsion solvent evaporation, researchers have developed HCTZ nanoparticles that significantly increase the drug's solubility compared to its bulk form . These nanoparticles, stabilized with surfactants like carboxymethyl dextran, have shown a 6.5-fold increase in solubility.
Self-Nanoemulsifying Drug Delivery Systems (SNEDDS)
Another innovative approach is the development of self-nanoemulsifying drug delivery systems (SNEDDS). These systems use a combination of oils, surfactants, and co-surfactants to form nano-sized emulsions that enhance the dissolution rate and diuretic activity of HCTZ. The optimized SNEDDS formulations have demonstrated improved pharmacodynamics and increased total urine volume compared to HCTZ alone .
Co-Amorphous Formulations
Co-amorphous formulations with amino acids like L-arginine and D-arginine have been investigated to improve the dissolution and permeability of HCTZ. These formulations create a supersaturated state, enhancing the drug's solubility and permeability through intermolecular interactions . The co-amorphous mixtures have shown better physical stability and dissolution properties, leading to improved permeation potential.
Cocrystals
Cocrystal engineering is another method used to enhance the physicochemical properties of HCTZ. Cocrystals with coformers such as nicotinic acid, nicotinamide, and 4-aminobenzoic acid have shown improved solubility and membrane permeability. These improvements are attributed to new drug-coformer interactions, which enhance the drug's overall biopharmaceutical profile .
Conclusion
Hydrochlorothiazide, a BCS Class IV drug, faces significant challenges due to its low solubility and permeability. However, various strategies such as cyclodextrin inclusion complexes, nanoparticle formulations, SNEDDS, co-amorphous formulations, and cocrystals have shown promise in enhancing its biopharmaceutical properties. These advancements could potentially improve the therapeutic efficacy and patient outcomes for those using HCTZ for hypertension management.
Sources and full results
Most relevant research papers on this topic
Inclusion complexes of hydrochlorothiazide and β-cyclodextrin: Physicochemical characteristics, in vitro and in vivo studies.
Using -cyclodextrin in inclusion complexes improves hydrochlorothiazide's solubility, stability, and biopharmaceutical properties, potentially enabling pediatric formulations.
DOI
Tablets of “Hydrochlorothiazide in Cyclodextrin in Nanoclay”: A New Nanohybrid System with Enhanced Dissolution Properties
The nanohybrid system of cyclodextrin and nanoclay significantly improves hydrochlorothiazide dissolution properties, resulting in a 12-fold increase in drug solubility compared to the commercial reference tablet Esidrex®.
Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.
Chlorthalidone and hydrochlorothiazide are considered interchangeable thiazide diuretics, but their pharmacokinetic and pharmacodynamic differences may cause differences in cardiovascular outcomes.
Preparation of Hydrochlorothiazide Nanoparticles for Solubility Enhancement
Hydrochlorothiazide nanoparticles with a particle size of 2.6 nm significantly enhance the solubility of the active ingredient, making it a promising tool for improving pharmaceutical formulations.
Self-Nanoemulsified Drug Delivery System of Hydrochlorothiazide for Increasing Dissolution Rate and Diuretic Activity
The self-nanoemulsifying drug delivery system (SNEDDS) for hydrochlorothiazide (HCTZ) effectively increases dissolution rate and diuretic activity, improving drug absorption and therapeutics.
Cocrystals of Hydrochlorothiazide: Solubility and Diffusion/Permeability Enhancements through Drug-Coformer Interactions.
Cocrystals of hydrochlorothiazide with NIC, NCT, PABA, SAM, and RES show improved solubility and diffusion/permeability, with the exception of SAM, which shows poor solubility and flux.
Hydrochlorothiazide Use and Skin Cancer: A Mohs Surgeon's Concern.
Hydrochlorothiazide use is associated with an increased risk of skin cancer, particularly in patients with a history of cutaneous carcinoma and hypertension.
DOI